Suppr超能文献

Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients with diabetic renal disease.

作者信息

Toto Robert D

机构信息

Division of Nephrology, Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-8856, USA.

出版信息

J Clin Hypertens (Greenwich). 2007 Nov;9(11 Suppl 4):16-25. doi: 10.1111/j.1524-6175.2007.07723.x.

Abstract

Hypertension is more prevalent and more difficult to control and is associated with a higher mortality rate in patients with diabetes than in nondiabetic patients. Elevated blood pressure contributes importantly to the development of albuminuria and progression of renal damage in diabetic nephropathy. Strong evidence indicates that the presence of albuminuria and overt nephropathy in patients with type 1 and type 2 diabetes is associated with a marked increase in the rate of fatal and nonfatal cardiovascular events. Blockade of the renin-angiotensin system in patients with type 2 diabetes with or without chronic kidney disease is associated with a significant reduction in risk for cardiovascular events. Renin-angiotensin system-blocking agents should be considered first-step pharmacologic therapy for hypertension in diabetic patients, with addition of other agents, if needed, to meet the recommended blood pressure goal of <130/80 mm Hg. In most instances, a diuretic is also needed to reduce blood pressure.

摘要

相似文献

1
Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients with diabetic renal disease.
J Clin Hypertens (Greenwich). 2007 Nov;9(11 Suppl 4):16-25. doi: 10.1111/j.1524-6175.2007.07723.x.
4
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Blood Purif. 2016;41(1-3):139-43. doi: 10.1159/000441264. Epub 2016 Jan 15.
7
[Risk and prevention of diabetic nephropathy].
G Ital Nefrol. 2007 Sep-Oct;24 Suppl 38:13-9.
8
The RAAS in the pathogenesis and treatment of diabetic nephropathy.
Nat Rev Nephrol. 2010 Jun;6(6):319-30. doi: 10.1038/nrneph.2010.58. Epub 2010 May 4.
9
Blood pressure control in diabetic nephropathy.
Contrib Nephrol. 2001(134):113-9. doi: 10.1159/000060141.
10
Antihypertensive strategy based on angiotensin II receptor blockers: a new gateway to reduce risk in hypertension.
Expert Rev Cardiovasc Ther. 2007 Jul;5(4):767-76. doi: 10.1586/14779072.5.4.767.

引用本文的文献

2
[Hypertension and the kidney].
Wien Med Wochenschr. 2008;158(13-14):359-64. doi: 10.1007/s10354-008-0558-3.

本文引用的文献

1
Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
Clin J Am Soc Nephrol. 2006 Sep;1(5):940-51. doi: 10.2215/CJN.00240106. Epub 2006 Jul 19.
3
Renin-angiotensin system and cardiovascular risk.
Lancet. 2007 Apr 7;369(9568):1208-19. doi: 10.1016/S0140-6736(07)60242-6.
4
KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.
Am J Kidney Dis. 2007 Feb;49(2 Suppl 2):S12-154. doi: 10.1053/j.ajkd.2006.12.005.
5
Standards of medical care in diabetes--2007.
Diabetes Care. 2007 Jan;30 Suppl 1:S4-S41. doi: 10.2337/dc07-S004.
6
Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
J Hypertens. 2006 Nov;24(11):2285-92. doi: 10.1097/01.hjh.0000249708.44016.5c.
7
Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.
Kidney Int. 2006 Aug;70(3):536-42. doi: 10.1038/sj.ki.5001580. Epub 2006 Jun 14.
9
Effect of aldosterone and MR blockade on the brain and the kidney.
Heart Fail Rev. 2005 Jan;10(1):53-62. doi: 10.1007/s10741-005-2349-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验